Tenaya Therapeutics (TNYA, Financial) is set to present interim findings from its RIDGE study, the largest of its kind focusing on arrhythmogenic right ventricular cardiomyopathy (ARVC) linked to Plakophilin 2 gene mutations. This data will be showcased at the Heart Rhythm Society’s annual event in San Diego, spanning April 24-27.
The RIDGE study aims to compile detailed information on participants' clinical profiles and medical records, alongside testing for preexisting antibodies to AAV9. This work is pivotal for the development of TN-401, a gene therapy targeting PKP2-associated ARVC, also referred to as arrhythmogenic cardiomyopathy (ACM). The therapy utilizes an adeno-associated virus serotype 9 (AAV9) to introduce a functional PKP2 gene into cardiac cells.
Simultaneously, Tenaya is progressing with its Phase 1b clinical trial, RIDGE-1, which is evaluating the safety, tolerability, and impact of a one-time TN-401 dose. Results regarding safety and biopsies from the initial patient group are anticipated in the latter half of 2025.
According to Tenaya's Chief Medical Officer, the RIDGE study not only offers crucial insights into ARVC but also acts as a valuable reference for evaluating TN-401's performance. This study serves as a bridge to enhance patient and clinical site engagement as the Phase 1b trial of TN-401 continues.
